{"id":"https://openalex.org/W4362592276","doi":"https://doi.org/10.1158/1538-7445.am2023-1594","title":"Abstract 1594: SMARCA2 (BRM) degraders promotes differentiation and inhibit proliferation in AML models","display_name":"Abstract 1594: SMARCA2 (BRM) degraders promotes differentiation and inhibit proliferation in AML models","publication_year":2023,"publication_date":"2023-04-04","ids":{"openalex":"https://openalex.org/W4362592276","doi":"https://doi.org/10.1158/1538-7445.am2023-1594"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2023-1594","doi":"https://doi.org/10.1158/1538-7445.am2023-1594","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2023-1594","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034853468","display_name":"Anjana Agarwal","orcid":"https://orcid.org/0009-0008-7625-1240","observed_orcids":["https://orcid.org/0009-0008-7625-1240"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anjana Agarwal","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065559317","display_name":"Olusola Peace Osinubi","orcid":"https://orcid.org/0009-0008-0221-5415","observed_orcids":["https://orcid.org/0009-0008-0221-5415"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olusola Peace Osinubi","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049083963","display_name":"Komali Vykuntam","orcid":"https://orcid.org/0009-0004-4538-4535","observed_orcids":["https://orcid.org/0009-0004-4538-4535"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Komali Vykuntam","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075101326","display_name":"Norman Fultang","orcid":"https://orcid.org/0000-0002-8115-7231","observed_orcids":["https://orcid.org/0000-0002-8115-7231"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Norman Fultang","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060435781","display_name":"Neha Bhagwat","orcid":"https://orcid.org/0009-0002-5766-0272","observed_orcids":["https://orcid.org/0009-0002-5766-0272"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neha Bhagwat","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103115213","display_name":"Diane Heiser","orcid":"https://orcid.org/0009-0008-1757-914X","observed_orcids":["https://orcid.org/0009-0008-1757-914X","https://orcid.org/0000-0003-1239-8936"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diane Heiser","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046355139","display_name":"Kris Vaddi","orcid":"https://orcid.org/0009-0009-8581-6511","observed_orcids":["https://orcid.org/0009-0009-8581-6511"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kris Vaddi","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023093205","display_name":"Koichi Ito","orcid":"https://orcid.org/0000-0003-1421-3122","observed_orcids":["https://orcid.org/0000-0003-1421-3122"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Koichi Ito","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018193992","display_name":"Peggy Scherle","orcid":"https://orcid.org/0000-0003-0783-6815","observed_orcids":["https://orcid.org/0000-0003-0783-6815"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peggy Scherle","raw_affiliation_strings":["1Prelude Therapeutics, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Wilmington, DE","institution_ids":["https://openalex.org/I4405265449"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405265449"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"83","issue":"7_Supplement","first_page":"1594","last_page":"1594"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.7103999853134155,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.7103999853134155,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.16820000112056732,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.11180000007152557,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/smarca2","display_name":"SMARCA2","score":0.7490000128746033},{"id":"https://openalex.org/keywords/brm","display_name":"BRM","score":0.9679999947547913},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.875},{"id":"https://openalex.org/keywords/protein-degraders","display_name":"protein degraders","score":0.7799999713897705},{"id":"https://openalex.org/keywords/swi-snf-chromatin-remodeling","display_name":"SWI/SNF chromatin remodeling","score":0.8759999871253967},{"id":"https://openalex.org/keywords/differentiation-therapy","display_name":"differentiation therapy","score":0.7870000004768372},{"id":"https://openalex.org/keywords/leukemia-stem-cells","display_name":"leukemia stem cells","score":0.843999981880188},{"id":"https://openalex.org/keywords/pu-1","display_name":"PU.1","score":0.9449999928474426},{"id":"https://openalex.org/keywords/monocyte-differentiation","display_name":"monocyte differentiation","score":0.6069999933242798},{"id":"https://openalex.org/keywords/cell-proliferation-inhibition","display_name":"cell proliferation inhibition","score":0.5740000009536743},{"id":"https://openalex.org/keywords/epigenetic-modifiers","display_name":"epigenetic regulators","score":0.7049999833106995},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.3449999988079071},{"id":"https://openalex.org/keywords/relapse-prevention","display_name":"relapse prevention","score":0.578000009059906}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.7026615738868713},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6329218149185181},{"id":"https://openalex.org/C80828422","wikidata":"https://www.wikidata.org/wiki/Q18031595","display_name":"SMARCA4","level":5,"score":0.5859653353691101},{"id":"https://openalex.org/C173396325","wikidata":"https://www.wikidata.org/wiki/Q1501275","display_name":"Gene knockdown","level":3,"score":0.5595676302909851},{"id":"https://openalex.org/C41091548","wikidata":"https://www.wikidata.org/wiki/Q26939","display_name":"Epigenetics","level":3,"score":0.5546860098838806},{"id":"https://openalex.org/C86339819","wikidata":"https://www.wikidata.org/wiki/Q407384","display_name":"Transcription factor","level":3,"score":0.5201287865638733},{"id":"https://openalex.org/C148738053","wikidata":"https://www.wikidata.org/wiki/Q210861","display_name":"Cellular differentiation","level":3,"score":0.5195915699005127},{"id":"https://openalex.org/C2779982571","wikidata":"https://www.wikidata.org/wiki/Q25098780","display_name":"Differentiation therapy","level":5,"score":0.5043832063674927},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.49796271324157715},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.495218425989151},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.449440062046051},{"id":"https://openalex.org/C83640560","wikidata":"https://www.wikidata.org/wiki/Q180951","display_name":"Chromatin","level":3,"score":0.44728535413742065},{"id":"https://openalex.org/C167227067","wikidata":"https://www.wikidata.org/wiki/Q5113739","display_name":"Chromatin remodeling","level":4,"score":0.433192640542984},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4110395312309265},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.3116426467895508},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.24010944366455078},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.19259214401245117},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.17361238598823547},{"id":"https://openalex.org/C2781121885","wikidata":"https://www.wikidata.org/wiki/Q425517","display_name":"Retinoic acid","level":3,"score":0.12699419260025024},{"id":"https://openalex.org/C2776601000","wikidata":"https://www.wikidata.org/wiki/Q612108","display_name":"Acute promyelocytic leukemia","level":4,"score":0.10849443078041077}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2023-1594","doi":"https://doi.org/10.1158/1538-7445.am2023-1594","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2023-1594","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4405042172","https://openalex.org/W4405039739","https://openalex.org/W4393088769","https://openalex.org/W7169761769","https://openalex.org/W4282982389","https://openalex.org/W2913043165","https://openalex.org/W4362543182","https://openalex.org/W4310103226","https://openalex.org/W4392390166","https://openalex.org/W4389241551"],"abstract_inverted_index":{"Abstract":[0],"Dysregulated":[1],"cellular":[2,19,165],"differentiation":[3,20,37,88,108,166,312,356],"is":[4],"a":[5,25,55,91,239,257],"major":[6],"pathological":[7],"feature":[8],"of":[9,35,58,66,75,81,159,178,201,236,279,306,319,366],"myeloid":[10,15,244],"malignancies":[11],"such":[12,36,323],"as":[13,24,44,46,107,141,143,289,291,324],"acute":[14],"leukemia":[16],"(AML).":[17],"Targeting":[18],"programs":[21],"has":[22,84,123],"emerged":[23],"novel":[26],"therapeutic":[27,321],"approach":[28],"to":[29,48,127,163,226,309,315],"treat":[30],"patients":[31,83],"with":[32,157,210,221,256,294],"AML.":[33],"Advantages":[34],"therapy":[38],"may":[39],"include":[40],"fewer":[41],"systemic":[42],"side-effects":[43],"well":[45,142,290],"opportunities":[47],"target":[49,310],"leukemic":[50,130],"stem":[51],"cells":[52],"(LSCs)":[53],"and":[54,68,77,114,134,152,167,275,286,314,326,357,379],"broader":[56],"range":[57],"clonal":[59],"populations,":[60],"likely":[61],"resulting":[62],"in":[63,70,79,94,169,190,206,219,243,250,270,299,328,360],"lower":[64],"frequencies":[65],"resistance":[67],"relapse":[69],"AML":[71,82,136,170,207,215,287,311,329,361],"patients.":[72,330],"The":[73],"success":[74],"ATRA":[76],"decitabine":[78,325],"subsets":[80],"proven":[85],"that":[86,184],"inducing":[87],"can":[89],"play":[90],"critical":[92],"role":[93],"long-term":[95],"durable":[96],"responses.":[97],"More":[98],"agents":[99,322],"targeting":[100,118],"epigenetic":[101],"regulators":[102],"have":[103,173],"been":[104,125],"increasingly":[105],"studied":[106],"inducers,":[109],"including":[110],"LSD1,":[111],"DNMT1,":[112],"Menin,":[113],"BET":[115],"inhibitors.":[116],"Recently,":[117],"SWI/SNF":[119,148],"chromatin":[120],"remodeling":[121],"complexes":[122],"also":[124],"shown":[126],"regulate":[128],"key":[129,240],"gene":[131,144],"expression":[132,235],"signatures":[133],"induce":[135],"differentiation.":[137],"Small":[138],"molecule":[139],"inhibitors":[140],"knockdown":[145],"for":[146,370],"ATP-dependent":[147],"subunits":[149],"SMARCA2":[150,182,187,203,211,231,258,280,307,352],"(BRM)":[151,353],"SMARCA4":[153],"(BRG1)":[154],"are":[155,297],"associated":[156],"re-direction":[158],"oncogenic":[160],"transcriptional":[161],"regulation":[162],"drive":[164],"apoptosis":[168],"models.":[171,192,208],"We":[172],"previously":[174],"described":[175],"the":[176,194,199,230,304,317,367],"activity":[177],"highly":[179],"potent,":[180],"bispecific":[181],"degraders":[183,205,212,308,354],"efficiently":[185],"promote":[186],"protein":[188],"degradation":[189],"preclinical":[191],"In":[193,229,248],"present":[195],"study,":[196],"we":[197],"investigated":[198],"effects":[200,282,293],"our":[202],"selective":[204,259],"Treatment":[209],"significantly":[213],"inhibits":[214],"cell":[216],"line":[217],"proliferation":[218,359],"vitro":[220],"IC50":[222],"ranging":[223],"from":[224],"10":[225],"50":[227],"nM.":[228],"degrader":[232,260,281],"treated":[233],"cells,":[234],"PU.1":[237],"(SPI1),":[238],"transcription":[241],"factor":[242],"leukemias,":[245],"was":[246],"downregulated.":[247],"an":[249],"vivo":[251],"OCI-AML3":[252],"xenograft":[253],"model,":[254],"treatment":[255],"showed":[261],"moderate":[262],"tumor":[263],"growth":[264],"inhibition":[265],"accompanied":[266],"by":[267],"robust":[268],"increases":[269],"monocytic":[271],"maturation":[272],"markers":[273],"CD11b":[274],"CD14.":[276],"Further":[277],"analyses":[278],"on":[283],"global":[284],"transcriptome":[285],"immunophenotypes":[288],"combination":[292],"other":[295,320],"therapies":[296],"currently":[298],"progress.":[300],"These":[301],"findings":[302],"highlight":[303],"potential":[305],"blocks":[313],"improve":[316],"effectiveness":[318],"venetoclax":[327],"Citation":[331],"Format:":[332],"Anjana":[333],"Agarwal,":[334],"Olusola":[335],"Peace":[336],"Osinubi,":[337],"Komali":[338],"Vykuntam,":[339],"Norman":[340],"Fultang,":[341],"Neha":[342],"Bhagwat,":[343],"Diane":[344],"Heiser,":[345],"Kris":[346],"Vaddi,":[347],"Koichi":[348],"Ito,":[349],"Peggy":[350],"Scherle.":[351],"promotes":[355],"inhibit":[358],"models":[362],"[abstract].":[363],"In:":[364],"Proceedings":[365],"American":[368],"Association":[369],"Cancer":[371,390],"Research":[372],"Annual":[373],"Meeting":[374],"2023;":[375],"Part":[376],"1":[377],"(Regular":[378],"Invited":[380],"Abstracts);":[381],"2023":[382],"Apr":[383],"14-19;":[384],"Orlando,":[385],"FL.":[386],"Philadelphia":[387],"(PA):":[388],"AACR;":[389],"Res":[391],"2023;83(7_Suppl):Abstract":[392],"nr":[393],"1594.":[394]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2023-04-06T00:00:00"}